이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

전이성 호르몬 민감성 전립선암에서 ADT와 ADT에 추가한 Darolutamide (ARANOTE)

2026년 9월 3일 업데이트: Bayer

전이성 호르몬 민감성 전립선암(mHSPC)이 있는 남성을 대상으로 안드로겐 차단 요법(ADT)과 위약 플러스 ADT에 추가한 Darolutamide의 무작위, 이중 맹검, 위약 대조 3상 연구

The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

연구 개요

상태

완전한

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

669

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Cape Town, 남아프리카, 7570
        • Cape Town Oncology Trials
    • Eastern Cape
      • Port Elizabeth, Eastern Cape, 남아프리카, 6045
        • Cancercare Langenhoven
    • Gauteng
      • Johannesburg, Gauteng, 남아프리카, 1475
        • East Rand Medical Research Unit
      • Pretoria, Gauteng, 남아프리카, 2
        • University of Pretoria, Clinical Research Unit
    • Bay of Plenty
      • Tauranga, Bay of Plenty, 뉴질랜드, 3112
        • Tauranga Urology Research Limited
    • Canterbury
      • Christchurch, Canterbury, 뉴질랜드, 8013
        • Canterbury Urology Research Trust
    • Waikato Region
      • Hamilton, Waikato Region, 뉴질랜드, 3240
        • Waikato Hospital
      • Changhua, 대만, 50006
        • Changhua Christian Hospital
      • Taichung, 대만, 40705
        • Taichung Veterans General Hospital
      • Tainan, 대만, 704
        • National Cheng Kung University Hospital
      • Taipei, 대만, 11217
        • Taipei Veterans General Hospital
    • Kaohsiung
      • Kaohsiung City, Kaohsiung, 대만, 807377
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Daugavpils, 라트비아, LV-5417
        • Daugavpils Regional Hospital
      • Riga, 라트비아, 1038
        • RAKUS Hospital Gailezers
      • Riga, 라트비아, LV-1001
        • URO Ltd.
      • Riga, 라트비아, LV-1002
        • P. Stradins Clinical University Hospital
      • Valmiera, 라트비아, LV-4201
        • Vidzemes Hospital
      • Arkhangelsk, 러시아 제국, 163045
        • Arkhangelsk Clinical Oncology Dispensary
      • Chelyabinsk, 러시아 제국, 454087
        • Chelyabinsk Regional Oncology Dispensary
      • Chelyabinsk, 러시아 제국, 454048
        • Ltd "EVIMED"
      • Ivanovo, 러시아 제국, 153040
        • Ivanovo Regional Oncology Dispensary
      • Kazan', 러시아 제국, 420029
        • Republican Clinical Oncology Dispensary Kazan
      • Moscow, 러시아 제국, 117997
        • Research Centre of X-ray and Radiology
      • Nizhny Novgorod, 러시아 제국, 603109
        • Volga District Med Center FMBA
      • Novosibirsk, 러시아 제국, 630099
        • LLC Reafan
      • Novosibirsk, 러시아 제국, 630099
        • Medical Center "Avicenna"
      • Omsk, 러시아 제국, 644013
        • Clinical Oncological Dispensary of Omsk Region
      • Saint Petersburg, 러시아 제국, 196006
        • AV Medical Group
      • Saint Petersburg, 러시아 제국, 197758
        • Russian Scientific Radiology and Surgery Technologies Center
      • Saint Petersburg, 러시아 제국, 197758
        • Scientific Research Instutute of Oncology n.a. N.N. Petrov
      • Tyumen, 러시아 제국, 625041
        • Multi-Field Clinical Medical Center "Medical City"
      • Ufa, 러시아 제국, 450054
        • Republican Clinical Oncology Dispensary
      • Vologda, 러시아 제국, 160022
        • Vologda Regional Hospital
      • Yekaterinburg, 러시아 제국, 620102
        • Sverdlovsk Regional Clinical Hospital #1
      • Kaunas, 리투아니아, LT-50009
        • The Hospital of Lithuanian University of Health SciencesLUHS
      • Klaipėda, 리투아니아, LT-92288
        • PI Klaipedos University Hospital
      • Vilnius, 리투아니아, LT-08660
        • National Cancer Institute
      • Vilnius, 리투아니아, LT-08661
        • Vilnius University Hospital Santaros Klinikos
      • Rio de Janeiro, 브라질, 22793-080
        • Instituto COI de Educação e Pesquisa
    • Estado de Bahia
      • Salvador, Estado de Bahia, 브라질, 41950-640
        • Assistência Multidisciplinar em Oncologia (AMO)
    • Goiás
      • Goiânia, Goiás, 브라질, 74605-070
        • Hosp. Araujo Jorge da Associação de Combate ao Câncer
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, 브라질, 30130-100
        • Hospital da Universidade Federal de Minas Gerais
      • Belo Horizonte, Minas Gerais, 브라질, 30150-270
        • Cetus Oncologia Hospital Dia
    • Paraná
      • Curitiba, Paraná, 브라질, 81520-060
        • Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, 브라질, 59040-000
        • Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica
    • Rio Grande do Sul
      • Pelotas, Rio Grande do Sul, 브라질, 96020-080
        • Unidade de Pesquisas Clinicas em Oncologia
      • Porto Alegre, Rio Grande do Sul, 브라질, 90850-170
        • Hospital Mae de Deus
      • Porto Alegre, Rio Grande do Sul, 브라질, 91350-280
        • FZ Pesquisa e Servicos em Cardiologia | Porto Alegre, Brazil
      • Porto Alegre, Rio Grande do Sul, 브라질, 90020-090
        • Santa Casa de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia
    • São Paulo
      • Barretos/SP, São Paulo, 브라질, 14784-400
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • São José do Rio Preto, São Paulo, 브라질, 15090-000
        • Hospital de Base | Funfarme - Centro Integrado de Pesquisa - Cardiologia
      • São Paulo, São Paulo, 브라질, 03102-002
        • IBCC - Instituto Brasileiro de Controle do Cancer
      • São Paulo, São Paulo, 브라질, 01243-020
        • Urobrasil
      • São Paulo, São Paulo, 브라질, 04039-004
        • Inst. de Assistência Médica ao Sérvidor Público Estadual
      • Barcelona, 스페인, 08025
        • Fundacio Puigvert | Urologia
      • Barcelona, 스페인, 08208
        • Parc Tauli Hospital Universitari | Oncologia
      • Cáceres, 스페인, 10003
        • Hospital San Pedro De Alcantara | Oncologia
      • Málaga, 스페인, 20910
        • Hospital Universitario Virgen De La Victoria | Urologia
      • Seville, 스페인, 41013
        • Hospital Universitario Virgen Del Rocio S.L. | Urologia
    • Madrid
      • Alcorcón, Madrid, 스페인, 28922
        • Hospital Universitario Fundacion Alcorcon | Urologia
      • Cherkasy, 우크라이나, 18009
        • CNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of the Cherkasy Regional Council"
      • Dnipro, 우크라이나, 49102
        • City Dnipropetrovsk Multi- field Clinical Hosp. 4 DSMA
      • Kyiv, 우크라이나, 4107
        • Kyiv Regional Oncological Dispensary
      • Kyiv, 우크라이나, 02660
        • Kyiv City Hospital #3 - Department of Urology
      • Chandigarh, 인도, 160012
        • Post Graduate Institute of Medical Education and Research
      • Kolkata, 인도, 700156
        • Tata Medical Center
      • Nashik, 인도, 422009
        • Apex Wellness Hospital
      • New Delhi, 인도, 110 085
        • Rajiv Gandhi Cancer Institute & Research Centre
    • Andhra Pradesh
      • Visakhapatnam, Andhra Pradesh, 인도, 530017
        • Mahatma Gandhi Cancer Hospital & Research Institute
    • Gujarat
      • Ahmedabad, Gujarat, 인도, 380016
        • The Gujarat Cancer & Research Institute
      • Ahmedabad, Gujarat, 인도, 380060
        • HCG Cancer Centre - Ahmedabad
      • Vadodara, Gujarat, 인도, 390007
        • Cancer Care Clinic - Vadodara
    • Karnataka
      • Belagavi, Karnataka, 인도, 590010
        • K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
      • Bengaluru, Karnataka, 인도, 560027
        • Healthcare Global Enterprises Ltd
    • Kerala
      • Kochi, Kerala, 인도, 682 041
        • Amrita Institute of Medical Sciences
      • Thiruvananthapuram, Kerala, 인도, 695011
        • Regional Cancer Centre - Thiruvananthapuram
    • Maharashtra
      • Chhatrapati Sambhajinagar, Maharashtra, 인도, 431001
        • Marathwada Regional Cancer Centre and Research Institute
      • Mumbai, Maharashtra, 인도, 400026
        • Jaslok Hospital and Research Centre
      • Nashik, Maharashtra, 인도, 422004
        • Curie Manavata Cancer Centre
      • Pune, Maharashtra, 인도, 411001
        • Jehangir Hospital
    • Odisha
      • Bhubaneswar, Odisha, 인도, 751019
        • All India Institute of Medical Sciences
      • Bhubaneswar, Odisha, 인도, 751007
        • Sparsh Hospital & Critical Care
    • Puducherry
      • Gorimedu, Puducherry, 인도, 605006
        • Jawaharlal Institute Of Postgraduate Medical Education and R
    • Punjab
      • Ludhiana, Punjab, 인도, 141008
        • Christian Medical Center & Hospital
    • Rajasthan
      • Jaipur, Rajasthan, 인도, 302017
        • Sawami Man Singh (SMS) Medical College & Attached Hospitals
    • Tamil Nadu
      • Madurai, Tamil Nadu, 인도, 625020
        • Apollo Speciality Hospitals
      • Madurai, Tamil Nadu, 인도, 625107
        • Meenakshi Mission Hospital & Research Centre
      • Beijing, 중국, 100142
        • Beijing Cancer Hospital
      • Beijing, 중국, 100083
        • Peking University Third Hospital
      • Beijing, 중국, 100000
        • Cancer Hospital, Chinese Academy of Medical Sciences
    • Anhui
      • Hefei City, Anhui Province, Anhui, 중국, 230031
        • Anhui Provincial Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100730
        • Beijing Hospital
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510000
        • Sun Yat-sen University Cancer Center
      • Guangzhou, Guangdong, 중국, 510180
        • Guangzhou First People Hospital
      • Shenzhen, Guangdong, 중국, 518172
        • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
    • Hubei
      • Wuhan, Hubei, 중국, 430030
        • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
      • Wuhan, Hubei, 중국, 430079
        • Hubei Cancer Hospital
      • Wuhan, Hubei, 중국, 430071
        • Zhongnan hospital ,Wuhan University
    • Hunan
      • Changsha, Hunan, 중국, 410013
        • Hunan Cancer Hospital - Oncology Department
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210008
        • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
      • Nantong, Jiangsu, 중국, 226361
        • Nantong tumor hospital
      • Suzhou, Jiangsu, 중국, 215004
        • The 2nd Affiliated Hospital of Soochow University
    • Jilin
      • Changchun, Jilin, 중국, 130021
        • 1st Hospital of Jilin University
    • Liaoning
      • Shengyang, Liaoning, 중국, 110042
        • Liaoning Cancer Hospital and Institute
    • Shandong
      • Yantai, Shandong, 중국, 264000
        • Yantai Yuhuangding Hospital
    • Shanxi
      • Xi’an, Shanxi, 중국, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
    • Sichuan
      • Chengdu, Sichuan, 중국, 610072
        • SichuanAcademyofMedicalSciences&SichuanProvincialPeople'sHos
      • Chengdu, Sichuan, 중국, MISSING
        • Sichuan University West China Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310000
        • The 1st Affiliated Hospital of Zhejiang University
      • Hangzhou, Zhejiang, 중국, 310014
        • ZheJiang Provincial People's Hospital
      • Ningbo, Zhejiang, 중국, 315010
        • Ningbo First Hospital
      • Wenzhou, Zhejiang, 중국, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Santiago, 칠레, 7510032
        • Oncovida
      • Santiago, 칠레
        • UROMED
      • Santiago, 칠레, TBC
        • Hospital Clínico de la Pontificia Univ. Católica de Chile
      • Santiago, 칠레, 7500921
        • Fundación Arturo López Perez
    • Araucania
      • Temuco, Araucania, 칠레, 4781156
        • Centro de Investigación Clínica del Sur
    • Santiago Metropolitan
      • Providencia, Santiago Metropolitan, 칠레, 7500653
        • Centro de Estudios Clínicos SAGA SpA
    • Valparaiso
      • Viña del Mar, Valparaiso, 칠레, 2520598
        • OncoCentro
    • Ontario
      • Burlington, Ontario, 캐나다, L7N 3V2
        • G. Kenneth Jansz Medicine Professional Corporation
    • Quebec
      • Montreal, Quebec, 캐나다, H2X 0A9
        • Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
      • Lima, 페루, LIMA 11
        • Hospital Militar Luis Arias Schreiber
      • Lima, 페루, LIMA 27
        • Clínica El Golf
    • Lima region
      • San Isidro, Lima region, 페루, 15036
        • Aliada
      • Santiago de Surco, Lima region, 페루, 15033
        • Hospital Guillermo Almenara Irigoyen
    • New South Wales
      • Kingswood, New South Wales, 호주, 2747
        • Nepean Hospital
      • St Leonards, New South Wales, 호주, 2065
        • Northern Cancer Institute
      • Sydney, New South Wales, 호주, 2109
        • Macquarie University Hospital - Oncology Department
    • South Australia
      • Adelaide, South Australia, 호주, 5000
        • Cancer Research South Australia
    • Victoria
      • Frankston, Victoria, 호주, 3199
        • Peninsula Oncology Centre
      • Heidelberg, Victoria, 호주, 3084
        • Austin Health

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of prostate
  • Metastatic disease
  • Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but not earlier than 12 weeks before randomization
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
  • Adequate bone marrow, liver and renal function

Exclusion Criteria:

  • Prior treatment with: LHRH agonist/antagonists except neoadjuvant and /or adjuvant therapy; Second-generation androgen receptor (AR) inhibitors such as enzalutamide, darolutamide, apalutamide or other investigational AR inhibitors; Cytochrome P17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as anti-cancer treatment for prostate cancer; Chemotherapy including docetaxel or immunotherapy for prostate cancer; Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days prior to randomization; Radiopharmaceuticals; Any other anti-cancer treatment for prostate cancer, excluding local therapies and ADT.
  • Treatment with radiotherapy within 2 weeks before randomization
  • Contraindication to iodinated CT and gadolinium chelate MRI intravenous contrast agent(s)
  • Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)
  • Uncontrolled hypertension as indicated by a resting systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite medical management
  • A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of study drug
  • Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization
  • Inability to swallow oral medications

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Darolutamide+ADT

Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy

Coated tablet, oral administration

Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy

위약 비교기: Placebo+ADT

Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy

Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy

Coated tablet matching Darolutamide in appearance, oral administration

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Radiological Progression-free Survival (rPFS) Assessed by Central Review
기간: From randomization to the date when 222 rPFS events were observed, approximately 36 months

rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria.

From randomization to the date when 222 rPFS events were observed, approximately 36 months

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: From randomization to the final analysis date, approximately 47 months

Time from the date of randomization to the date of death from any cause.

From randomization to the final analysis date, approximately 47 months
Time to Castration-Resistant Prostate Cancer (CRPC)
기간: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first).

From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to Initiation of Subsequent Anti-cancer Therapy
기간: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer.

From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to PSA Progression
기간: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level <0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels <0.50 ng/mL is requested at initial assessment.

From randomization to the date when 222 rPFS events were observed, approximately 36 months
PSA Undetectable Rates (<0.2 ng/mL)
기간: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values <0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline.

From randomization to the date when 222 rPFS events were observed, approximately 36 months
Time to Pain Progression
기간: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale [WPS]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS >0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization.

From randomization to the date when 222 rPFS events were observed, approximately 36 months
Number of Participants With Adverse Events as a Measure of Safety
기간: From start of study drug administration until 30 days after the last administration

An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug.

From start of study drug administration until 30 days after the last administration

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 2월 23일

기본 완료 (실제)

2024년 6월 7일

연구 완료 (실제)

2026년 1월 23일

연구 등록 날짜

최초 제출

2021년 1월 29일

QC 기준을 충족하는 최초 제출

2021년 1월 29일

처음 게시됨 (실제)

2021년 2월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 3일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 21140
  • 2020-003093-48 (EudraCT 번호)
  • 2022-502244-12-00 (기타 식별자: CTIS (EU))

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .